micafungin
alon
combin
anoth
system
antifung
agent
criteria
ia
therapeut
respons
judg
independ
panel
result
patient
enrol
met
diagnost
criteria
ia
determin
independ
panel
receiv
least
one
dose
micafungin
patient
includ
undergon
hematopoiet
stem
cell
transplant
hsct
allogen
graft
versu
host
diseas
gvhd
receiv
chemotherapi
hematolog
malign
favor
respons
rate
end
therapi
seen
patient
treat
micafungin
favor
respons
seen
primari
salvag
therapi
group
correspond
number
combin
treatment
group
primari
salvag
treatment
group
respect
micafungintr
patient
die
therapi
followup
phase
death
attribut
ia
conclus
micafungin
primari
salvag
therapi
prove
efficaci
safe
highrisk
patient
ia
although
patient
number
small
micafunginonli
group
micafungin
alon
combin
system
antifung
agent
treatment
acut
invas
aspergillosi
keyword
micafungin
echinocandin
aspergillosi
antifung
combin
amphotericin
b
summari
background
micafungin
new
lipopeptid
compound
echinocandin
activ
aspergillu
candida
speci
studi
evalu
safeti
efficaci
micafungin
patient
proven
probabl
invas
aspergillosi
ia
method
multin
noncompar
studi
conduct
examin
proven
probabl
pulmonari
aspergillu
speci
infect
wide
varieti
patient
popul
studi
employ
openlabel
design
util
invas
aspergillosi
ia
lifethreaten
infect
often
occur
adult
children
signific
immunosuppress
particularli
relat
neutropenia
corticosteroid
treatment
frequenc
ia
vari
substanti
one
risk
group
anoth
local
perhap
influenc
diagnost
approach
taken
given
unit
recent
exampl
incid
highrisk
group
includ
acut
myeloid
leukemia
acut
lymphocyt
leukemia
autolog
hematopoiet
stem
cell
transplant
hsct
allogen
stem
cell
transplant
nonmyeloabl
condit
allogen
hsct
myeloabl
condit
lung
transplant
heart
lung
small
bowel
transplant
liver
transplant
acquir
immunodefici
syndrom
aid
increasingli
recogn
risk
group
includ
medic
intens
care
unit
patient
chronic
pulmonari
diseas
treat
corticosteroid
receiv
antitumor
necrosi
factor
monoclon
antibodi
therapi
infliximab
sever
acut
respiratori
syndrom
sar
mortal
due
ia
high
review
case
report
crude
mortal
rate
pulmonari
sinu
cerebr
aspergillosi
respect
occasion
report
improv
seen
sinc
despit
introduct
new
agent
last
year
micafungin
new
lipopeptid
compound
echinocandin
synthes
chemic
modif
product
coleophoma
empetri
antifung
activ
resid
cell
wall
inhibit
synthesi
betadglucan
preclin
studi
indic
micafungin
fungicid
activ
almost
candida
speci
includ
azoleresist
candida
albican
kill
grow
tip
aspergillu
speci
like
echinocandin
median
minimum
inhibitori
concentr
mic
valu
aspergillu
speci
includ
aspergillu
fumigatu
aspergillu
flavu
aspergillu
niger
aspergillu
terreu
substanti
lower
nonechinocandin
test
ie
mgml
compar
mgml
amphotericin
b
indic
potenti
greater
clinic
activ
itraconazol
amphotericin
b
clinic
isol
murin
model
ia
fumigatu
terreu
micafungin
highli
effect
prevent
mortal
superior
liposom
amphotericin
b
terreu
infect
although
cultur
tend
remain
posit
tissu
dose
respons
mgkg
mg
kg
observ
micafungin
also
shown
confer
synergist
activ
amphotericin
b
vitro
murin
aspergillosi
model
initi
studi
male
volunt
adult
hsct
recipi
human
immunodefici
viru
hiv
patient
indic
micafungin
well
toler
wide
rang
dose
object
current
studi
evalu
safeti
efficaci
micafungin
administ
alon
combin
system
antifung
agent
patient
proven
probabl
invas
infect
due
aspergillu
speci
studi
util
two
ident
protocol
two
except
see
europ
protocol
rest
world
openlabel
noncompar
multin
studi
adult
pediatr
patient
enrol
ethic
approv
obtain
particip
site
studi
design
demonstr
safeti
efficaci
micafungin
treatment
acut
ia
fail
respond
prior
therapi
label
refractori
inadequ
respons
failur
h
system
antifung
therapi
patient
unabl
take
altern
therapi
advers
event
associ
therapi
label
toxic
failur
addit
patient
newli
diagnos
ia
receiv
h
system
antifung
therapi
elig
enrol
patient
label
primari
adult
pediatr
patient
age
except
prematur
neonat
proven
probabl
invas
infect
due
aspergillu
speci
enrol
patient
pulmonari
aspergillosi
could
enrol
probabl
case
european
protocol
patient
year
age
patient
classifi
primari
exclud
proven
ia
defin
either
tissu
infect
site
show
hypha
consist
aspergillu
spp
without
confirmatori
cultur
site
posit
cultur
steril
site
ie
percutan
aspir
probabl
ia
pertain
pulmonari
infect
defin
clinic
featur
ia
either
radiolog
featur
consist
diagnosi
posit
respiratori
cultur
sputum
bronchoalveolar
lavag
patient
exclud
studi
pregnant
nurs
markedli
abnorm
liver
test
paramet
defin
transaminas
upper
limit
normal
uln
total
bilirubin
uln
alkalin
phosphatas
uln
life
expect
judg
less
day
administ
intraven
either
inpati
outpati
set
base
result
earlier
studi
patient
receiv
micafungin
daili
infus
initi
dose
mg
per
day
mgkg
per
day
patient
weigh
kg
continu
posit
cultur
find
patient
experienc
progress
diseas
improv
base
clinic
sign
symptom
micafungin
well
toler
dose
micafungin
could
increas
mg
increment
mgkg
per
day
increment
patient
weigh
kg
least
day
dose
micafungin
investig
discret
patient
enrol
noneuropean
protocol
dose
increas
mg
mgkg
per
day
patient
weigh
kg
requir
approv
medic
monitor
dose
escal
allow
mg
per
day
patient
enrol
european
protocol
micafungin
administ
intraven
least
day
maximum
day
unless
extens
approv
sponsor
medic
monitor
intermitt
dose
daili
dose
minimum
day
week
permit
respons
micafungin
record
event
daili
therapi
longer
possibl
durat
followup
posttreat
week
refractori
patient
could
receiv
micafungin
alon
addit
current
system
antifung
therapi
without
alter
dose
prepar
discret
investig
patient
toxic
failur
group
micafungin
dose
commenc
discontinu
previou
system
antifung
agent
patient
underw
blood
collect
determin
clinic
laboratori
profil
baselin
schedul
time
therapi
week
follow
treatment
advers
event
h
last
administr
studi
drug
whether
ascertain
patient
interview
physic
examin
laboratori
find
mean
record
ongo
advers
event
follow
long
necessari
adequ
evalu
patient
safeti
event
stabil
advers
event
code
use
modifi
code
system
thesauru
advers
reaction
term
costart
dictionari
tabul
patient
group
age
group
relationship
studi
drug
intens
patient
discontinu
studi
drug
independ
review
conduct
three
review
dwd
tfp
kam
object
provid
consist
assess
baselin
diagnosi
ia
diseas
statu
studi
entri
efficaci
failur
patient
efficaci
outcom
follow
micafungin
treatment
causal
death
regard
aspergillosi
patient
classifi
primari
efficaci
failur
refractori
toxic
failur
primari
patient
receiv
h
less
prior
antifung
therapi
infect
efficaci
failur
patient
infect
progress
fail
improv
therapeut
dose
system
antifung
therapi
least
h
toxic
failur
patient
signific
renal
hepat
toxic
time
micafungin
start
furthermor
refractori
patient
categor
two
group
patient
receiv
micafungin
addit
current
antifung
therapi
combin
therapi
patient
receiv
micafungin
micafungin
alon
primari
endpoint
treatment
success
end
therapi
respons
categor
complet
respons
cr
partial
respons
pr
stabil
diseas
failur
f
base
radiolog
mycolog
clinic
respons
failur
criteria
respons
ident
use
evalu
respons
caspofungin
two
review
common
independ
panel
favor
respons
defin
complet
partial
respons
reemerg
aspergillu
infect
new
fungal
infect
use
addit
antifung
therapi
posttreat
period
also
assess
causal
death
assess
regard
aspergillu
infect
two
analys
prespecifi
patient
receiv
least
one
dose
micafungin
full
analysi
set
fa
includ
safeti
analysi
per
protocol
set
pp
defin
patient
proven
probabl
ia
baselin
receiv
least
seven
dose
studi
drug
patient
receiv
least
one
dose
studi
drug
met
protocolspecifi
criteria
determin
independ
review
panel
analyz
modifi
full
analysi
set
mfa
treatment
success
rate
base
global
assess
efficaci
end
therapi
follow
independ
review
twosid
confid
interv
ci
construct
base
larg
sampl
normal
approxim
binomi
distribut
primari
endpoint
analyz
key
demograph
variabl
fungal
infect
risk
factor
select
laboratori
data
includ
hematolog
serum
chemistri
data
tabul
patient
group
primari
efficaci
failur
micafungin
efficaci
failur
micafungin
alon
toxic
failur
summari
statist
assess
time
chang
baselin
gener
total
patient
enrol
studi
unit
state
germani
brazil
canada
unit
kingdom
seven
south
africa
five
franc
four
itali
three
peru
two
spain
two
sweden
patient
receiv
least
one
dose
studi
drug
evalu
fa
pp
compris
patient
proven
probabl
ia
infect
baselin
receiv
least
seven
dose
studi
drug
patient
receiv
least
one
dose
studi
drug
exclud
diagnosi
meet
protocolspecifi
criteria
determin
independ
review
panel
result
patient
compris
mfa
e
patient
proven
probabl
ia
infect
baselin
receiv
least
one
dose
studi
drug
demograph
patient
enrol
mfa
describ
tabl
note
subject
children
age
year
youngest
patient
enrol
month
age
oldest
year
patient
profound
neutropenia
enrol
although
primari
risk
factor
ia
thirtysix
patient
profound
neutropenia
baselin
recoveri
neutropenia
treatment
micafungin
time
recoveri
record
systemat
within
mfa
group
patient
ia
micafungin
use
primari
therapi
among
mfa
patient
enrol
refractori
patient
four
toxic
failur
refractori
patient
document
progress
stabl
diseas
baselin
four
indetermin
independ
review
patient
fa
demonstr
complet
partial
respons
howev
detail
analysi
efficaci
result
report
base
mfa
defin
independ
review
panel
unless
otherwis
note
total
patient
achiev
favor
respons
addit
patient
experienc
stabil
diseas
tabl
favor
respons
cr
pr
seen
base
investig
global
assess
end
therapi
highest
rate
success
toxic
failur
group
importantli
primari
therapi
group
respond
five
receiv
combin
therapi
six
receiv
micafungin
monotherapi
tabl
one
half
patient
experienc
progress
fungal
infect
studi
favor
respons
patient
treat
micafungin
refractori
patient
primari
patient
four
toxic
failur
patient
seen
favor
respons
observ
patient
mfa
least
one
dose
increas
initi
dose
mg
per
day
independ
review
attempt
assess
impact
surgeri
might
made
respons
assess
base
natur
surgeri
locat
diseas
postsurg
find
mfa
patient
invas
surgeri
review
consid
possibl
impact
patient
posit
nonleth
outcom
advers
event
consid
investig
possibl
probabl
relat
studi
drug
report
patient
overal
common
studi
drugrel
advers
event
bilirubinemia
nausea
vomit
increas
serum
glutam
pyruv
transaminas
sgpt
increas
alkalin
phosphatas
diarrhea
hypertens
total
patient
advers
event
consid
investig
relat
studi
drug
least
one
advers
event
moder
sever
intens
patient
least
one
advers
event
consid
life
threaten
treatment
stop
due
advers
event
patient
includ
children
advers
event
consid
relat
studi
drug
lead
studi
drug
discontinu
describ
tabl
patient
enrol
die
therapi
followup
phase
death
consid
attribut
ia
anoth
caus
ia
death
anoth
caus
without
aspergillosi
indetermin
caus
common
primari
direct
caus
death
sepsi
thirtyfour
patient
die
therapi
due
ia
patient
die
micafungin
treatment
stop
due
ia
howev
posttreat
death
week
follow
micafungin
discontinu
relat
decis
withdraw
support
institut
anoth
unsuccess
antifung
treatment
ten
patient
die
due
nonaspergillu
fungal
infect
nonaspergillu
fungal
infect
contribut
patient
death
five
patient
mucormycosi
two
alternaria
sp
one
chaetomium
sp
one
scedosporium
sp
one
invas
scopulariopsi
two
patient
multipl
fungal
organ
contribut
death
one
patient
aspergillu
rhizopu
one
aspergillu
candida
total
patient
mfa
assess
followup
visit
patient
complet
partial
respons
studi
design
prospect
openlabel
noncompar
multin
studi
studi
initi
prior
licens
voriconazol
caspofungin
rariti
diseas
usual
hinder
rapid
patient
accrual
therapeut
area
fact
patient
enrol
less
year
center
result
efficaci
safeti
inform
wide
varieti
aspergillu
speci
infect
patient
popul
obtain
although
previou
trial
caspofungin
enrol
patient
alreadi
publish
paper
describ
largest
therapeut
studi
date
ia
treat
echinocandin
independ
review
patient
mfa
demonstr
complet
partial
respons
micafungin
compar
modifi
intenttotreat
result
seen
caspofungin
consensu
enrol
criteria
clinic
failur
salvag
acut
ia
instanc
mani
day
primari
therapi
necessari
primari
therapi
consid
failur
also
varieti
atrisk
popul
extent
diseas
present
includ
extrapulmonari
dissemin
make
uniform
definit
suspect
patient
extens
pulmonari
infect
diagnosi
usual
fatal
worsen
diseas
synonym
death
inde
prospect
studi
acut
ia
includ
studi
earli
death
constant
featur
patient
limit
singl
multifoc
diseas
typic
respond
well
treatment
even
enlarg
volum
shrink
fact
rapidli
progress
pulmonari
lesion
enlarg
first
day
antifung
therapi
make
realist
earli
determin
respons
difficult
likewis
fever
clinic
sign
often
take
sever
day
start
resolv
present
studi
patient
least
day
antifung
therapi
enrol
patient
howev
heavili
pretreat
exampl
patient
receipt
lipid
amphotericin
b
actual
receiv
mean
day
therapi
mean
dose
mgkg
immedi
prior
enrol
heterogen
previou
therapi
extent
progress
natur
diseas
differ
underli
poor
prognost
factor
plan
independ
review
place
patient
differ
categori
facilit
comparison
studi
one
categori
primari
treatment
group
respond
anoth
categori
efficaci
failur
refractori
patient
unfortun
purpos
analysi
patient
group
receiv
caspofungin
assess
modifi
intentiontotreat
analys
combin
therapi
ia
much
discuss
publish
data
describ
use
combin
therapi
human
subject
data
describ
use
micafungin
part
combin
therapi
avail
despit
support
vitro
vivo
studi
primari
argument
consid
combin
treatment
enhanc
overal
respons
rate
secondari
argument
includ
increas
antifung
spectrum
empir
therapi
encompass
pathogen
includ
resist
fungi
realiz
better
pharmacodynam
paramet
one
agent
anoth
certain
bodi
site
prevent
develop
resist
possibl
abl
use
reduc
dose
one
drug
without
loss
activ
minim
toxic
time
studi
perform
physician
like
use
combin
therapi
ill
patient
high
mortal
probabl
probabl
happen
trial
physician
choic
add
substitut
micafungin
refractori
case
amphotericin
btreat
patient
amphotericin
b
deoxychol
lipidassoci
amphotericin
treat
combin
micafungin
amphotericin
prepar
respond
past
hsct
patient
ia
report
poor
prognosi
even
late
clinic
success
rate
suggest
larg
survey
patient
popul
favor
respons
micafungin
usual
combin
anoth
agent
seen
allogen
hsct
patient
recent
prospect
studi
singl
drug
caspofungin
treatment
yield
salvag
respons
rate
compar
voriconazol
amphotericin
b
primari
therapi
respons
rate
respect
data
alway
avail
evalu
detail
host
risk
known
impact
prognosi
therapi
sever
graft
versu
host
diseas
gvhd
cumul
exposur
steroid
relaps
malign
graft
failur
initi
dose
mg
per
day
micafungin
use
studi
would
consid
rel
lowtreat
dose
nevertheless
among
patient
mfa
dose
increas
initi
dose
mg
per
day
mgkg
patient
kg
respond
initi
dose
micafungin
partial
effect
regardless
patient
group
primari
versu
efficaci
failuretox
failur
sitespeci
infect
increas
dose
micafungin
appar
effect
achiev
therapeut
respons
number
patient
patient
dose
increas
favor
respons
seen
includ
primari
efficaci
failur
patient
mean
daili
dose
exceed
mg
per
day
without
signific
toxic
micafungin
proven
efficaci
treatment
esophag
candidiasi
candidemia
prophylaxi
candidemia
patient
undergo
hsct
studi
demonstr
micafungin
primarili
combin
amphotericin
b
efficaci
treatment
acut
ia
adult
pediatr
patient
fail
respond
prior
therapi
patient
unabl
toler
altern
therapi
micafungin
alon
combin
amphotericin
b
gener
well
toler
result
suggest
micafungin
either
alon
combin
viabl
option
treatment
invas
aspergillosi
random
trial
necessari
determin
combin
therapi
add
therapeut
benefit
one
drug
alon
